$VERUJun 4, 2026, 12:30 PMAI processed8-K
Veru secures free Wegovy supply from Novo Nordisk for Phase 2b PLATEAU
AI Summary
VERU INC. filed SEC Form 8-K. Veru entered a clinical supply agreement with Novo Nordisk under which Novo will supply Wegovy (semaglutide) at no charge as required for Veru’s Phase 2b PLATEAU study while Veru will sponsor and conduct the trial. Veru retains full global development and commercialization rights to enobosarm but granted Novo Nordisk a right of first negotiation for any future development/commercialization of enobosarm combined with a Novo GLP‐1 product; the agreement can be terminated by Novo Nordisk for convenience with 60 days' prior notice.
Positives
- Novo Nordisk will supply Wegovy to Veru at no charge for use in the Phase 2b PLATEAU study
- Veru is sole sponsor and retains full global development and commercialization rights to enobosarm
- Agreement provides Veru access to Wegovy for the trial without drug purchase costs
Negatives
- Veru remains solely responsible for conducting and sponsoring (and implicitly funding) the Phase 2b trial
- Novo Nordisk can terminate the supply agreement for convenience with 60 days' prior notice
- Veru granted Novo Nordisk a right of first negotiation for any future enobosarm combinations with Novo GLP‑1 products